Fall into wellness: Preventive health tips for older adults, a Q&A with Jean Reidy
This article provides preventive health tips for older adults as fall approaches, featuring a Q&A with Jean Reidy, an Adult Nurse Practitioner at Oak Street Health. She emphasizes the importance of annual wellness visits, recommended vaccinations, and preventive screenings. Reidy also highlights the significance of mental health awareness, especially during colder months, and encourages proactive healthcare steps.
Certain Options of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026.
This article announces that certain options of Amylyx Pharmaceuticals, Inc. are under a lock-up agreement, set to expire on October 4, 2026. The lock-up period began on August 19, 2026, and prevents the disposal or hedging of shares by company officers and directors without prior consent from specific financial institutions. This measure is standard for newly public companies to stabilize stock performance after an offering.
Cigna Group (CI) Could Be 58% Undervalued On PBM And Claims Review Concerns
Cigna Group (CI) stock performance has trended lower recently, with a 1-year total shareholder return down 11.04%, despite a 44.70% gain over five years. The company's fair value is estimated at $636.28, significantly higher than its recent closing price of $270.53, suggesting it is 58% undervalued. This undervaluation is attributed to market concerns including political hostility towards PBMs, restrictions on Express Scripts, uncertainty around automated claims review, declining customer counts, and uneven cash conversion.
Progyny Inc. Stock Grades | PGNY
This article provides a stock overview for Progyny Inc. (PGNY), including its stock grades, analyst ratings, key financial metrics such as market value, EPS, and P/E ratio, and a brief company description. It also lists peer companies and data providers.
Boston Scientific Corporation (BSX) Stock forecasts
This article provides an analyst report on Boston Scientific Corporation (BSX) by Morningstar. The report, dated October 2, 2026, highlights competitive pressures affecting key growth areas for the company, which specializes in less invasive medical devices. Debbie S. Wang, a Senior Equity Analyst, authored the report.
The employer imperative: Addressing the unmet needs of employees with cancer
This article emphasizes the growing need for employers to support employees facing cancer, as more individuals are diagnosed at working age. It highlights that many employees with cancer miss essential preventive screenings and mental health care, often unaware of available employer resources. The piece urges employers to improve support by clarifying preventive care benefits, strengthening mental health services, and promoting comprehensive cancer care resources.
Critical Metals Corp. Announces Death of Michael C. Ryan, Director on September 27, 2026
Critical Metals Corp. announced the passing of Michael C. Ryan, a director on its Board of Directors, on September 27, 2026. Mr. Ryan had served on the board since February 2025. The company shared the news through an S&P Capital IQ release.
Piper Sandler maintains Overweight rating on Cigna Group, $370 price target
Piper Sandler has reiterated its Overweight rating for Cigna Group, setting a price target of $370.00, which suggests a potential upside of 38.1% from its recent closing price. This positive outlook is supported by Cigna's long-term adjusted EPS growth target of 10.0-14.0% through CY30 and a new adjusted EPS floor of at least $45.00 for CY30. Additionally, the company's $3.0 billion efficiency initiative is expected to significantly contribute to sustainable earnings growth and long-term financial targets.
Humana Inc. Research & Ratings | HUM
This article provides research and ratings for Humana Inc. (HUM), including analyst ratings, price targets, stock performance data, and financial estimates. It details the company's segments, key financial figures like EPS and dividend yield, and compares it to peers in the health insurance sector.
Grail’s cancer blood test nears landmark FDA approval, but insurance coverage looms
Grail's Galleri blood test is close to FDA approval, which would be a significant step towards wider adoption. However, securing health insurance coverage from both private insurers and government programs like Medicare is the next major hurdle for the multi-cancer early detection test. Widespread coverage could lead to a multi-billion dollar market, but concerns remain regarding follow-up costs, uncertain benefits, and the need for further research to confirm its impact on reducing cancer deaths.
Certain Warrants of Datacentrex, Inc. are subject to a Lock-Up Agreement Ending on 2-OCT-2026.
This article announces that certain warrants of Datacentrex, Inc. are subject to a lock-up agreement ending on October 2, 2026. The lock-up period for these warrants began on March 31, 2026, and lasts for 185 days. Executive officers and directors have agreed not to transfer or dispose of equity securities during this period without prior consent.
B. Riley Downgrades Priority Technology Holdings to Neutral From Buy, Cuts Price Target to $8.05 From $11
B. Riley has downgraded Priority Technology Holdings (PRTH) from a "Buy" rating to "Neutral" and reduced its price target to $8.05 from $11. This decision comes amidst recent news of Priority Technology's plan to go private in a $1.6 billion CEO-led deal. The article also provides a company profile, recent news, and financial data for Priority Technology Holdings.
How Much Downside Is Left In CVS Health Stock?
CVS Health stock has fallen 12.7% in the past month, trading 22.5% below its 52-week high, despite no company-specific news. The article analyzes CVS's current financial state, noting its thin operating margins and heavy debt, which amplifies market risk. It also reviews CVS's historical performance during market shocks, particularly credit crises, where it experienced significant declines but eventually recovered.
HCA Healthcare (NYSE:HCA) Stock Crosses Above Two Hundred Day Moving Average - Here's Why
HCA Healthcare (NYSE:HCA) shares recently surpassed their 200-day moving average, reaching $434.46 with a consensus "Moderate Buy" rating and an average analyst target of $463.70. The company reported strong Q1 2026 operating results, including an 8.7% year-over-year revenue increase to $20.23 billion and earnings of $7.59 per share, exceeding estimates. Despite positive developments like a new breast-health joint venture and AI tool expansion, investors face risks from a Pomerantz investigation and an ongoing contract dispute with Cigna in Houston.
Cigna (CI) Stock Looks Cheap Following Its 44% Five Year Gain
Cigna (CI) has seen a 43.7% gain over the past five years, but its stock is down in the last year, leading to questions about its current valuation relative to earnings. Despite a new US$3 billion modernization program and reaffirmed 2026 guidance, Cigna's P/E ratio of 11.0x is significantly lower than the broader Healthcare sector (24.3x) and its peer group (29.8x), suggesting it may be undervalued. Investors are encouraged to consider Cigna's future growth potential and analyst expectations to determine if its earnings justify its current price.
Elutia Reports $8 Million Payment from Boston Scientific
Elutia Inc. has reported receiving an $8 million payment from Boston Scientific. The article, published on MarketScreener, notes Elutia's recent activities including the acquisition of its SimpliDerm business by Cellution Biologics for $11 million and securing a $15 million loan to fund the launch of its NXT-41X product. Elutia is a commercial-stage company focused on developing proprietary drug-eluting biomatrix products for surgical reconstruction.
UBS reiterates Cigna stock buy rating on 2026-2030 outlook
UBS has reaffirmed its Buy rating and $400 price target for Cigna Group (NYSE:CI), citing the company's strong outlook through 2030. Cigna projects adjusted earnings per share (EPS) of at least $30.45 in 2026, with a target of 10% to 14% adjusted EPS compound annual growth rate through 2030, and a minimum of $45 adjusted EPS by 2030. The positive outlook is supported by share buybacks, modernization improvements, and robust performance in its various segments.
Texas AG opens prior auth probe into Blue Cross Blue Shield of Texas
Texas Attorney General Ken Paxton has launched an investigation into Blue Cross Blue Shield of Texas (BCBSTX) regarding its prior authorization and care denial processes. The probe follows numerous reports of denied or delayed coverage for medically necessary services, including a case involving a newborn. Paxton stated that the investigation aims to determine if BCBSTX has violated Texas law, emphasizing the importance of patient care over profits.
RBC Capital reiterates Outperform rating on Cigna Group, $337 price target
RBC Capital has reaffirmed its Outperform rating for Cigna Group (CI) and set a price target of $337. This target suggests a 24.0% upside from Cigna's closing price on September 30. Key factors contributing to this positive outlook include strong growth potential in Cigna's Specialty and Care Services segment, projected to exceed 40% of enterprise earnings by 2030, and an integrated care model that enhances patient engagement and supports cost savings for employers.
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
Shares of United Therapeutics Corp. are rising after a federal court ruled in its favor in a patent infringement lawsuit against Liquidia Corp. The court found that Liquidia induced infringement of United Therapeutics' patent related to inhaled treprostinil for pulmonary hypertension, leading to potential withdrawal of Liquidia's Yutrepia from the U.S. market for that indication and a BTIG analyst upgrade for United Therapeutics.
Mizuho Trims Price Target on Eastman Chemical to $80 From $85, Keeps Outperform Rating
Mizuho has reduced its price target for Eastman Chemical Company (EMN) to $80 from $85, while maintaining an "Outperform" rating on the stock. This adjustment comes amidst other recent analyst revisions for Eastman Chemical, with some increasing and others decreasing their price targets. Eastman Chemical is a global specialty materials company reporting its Q2 2026 earnings with adjusted EPS and revenue rising.
Jefferies Adjusts Price Target on Cigna Group to $288 From $307, Keeps Hold Rating
Jefferies has lowered its price target for The Cigna Group (CI) to $288 from $307, while maintaining a "Hold" rating on the stock. This adjustment follows recent news regarding Cigna's long-term financial targets and guidance. The healthcare company also announced expectations for significant cost savings and adjusted revenues in the coming years.
Healthcare Services Group (NASDAQ:HCSG) Stock Rating Cut to Hold at Zacks Research
Zacks Research has downgraded Healthcare Services Group (NASDAQ:HCSG) from a "strong buy" to a "hold" rating, aligning with a similar move by Wall Street Zen. Despite this, the stock maintains a consensus "moderate buy" rating with an average price target of $26.50. The company reported strong quarterly earnings, exceeding estimates, but revenue slightly missed forecasts.
Radiopharm Theranostics : Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
Radiopharm Theranostics has released its Annual Report for the fiscal year ending June 30, 2026. The company experienced a total comprehensive loss of A$56.3 million, an increase from A$37.9 million in fiscal 2025, primarily due to increased research and development expenses which reached A$49.9 million in 2026. Despite the losses, the company secured an At the Market (ATM) facility to raise up to US$9.3 million, intending to fund operations with minimal shareholder dilution.
HCA Houston and Cigna locked in new contract dispute with deal set to expire
HCA Houston Healthcare and Cigna are currently in a contract dispute, with their current agreement set to expire on October 1st. If a new deal is not reached, HCA's hospitals and surgical centers in Houston will no longer be part of Cigna's network. This standoff comes two years after their previous agreement was signed.
What Cigna Group (CI)'s $3 Billion Modernization Plan Means For Shareholders
Cigna Group announced a $3 billion "Lead to One" modernization and productivity program at its 2026 Investor Day, targeting complex care capabilities and operational efficiency. This investment aims to reshape the narrative around its Evernorth and Signature businesses, offsetting pressures from medical cost trends and the exit from the individual ACA exchange. Shareholders will be watching for tangible outcomes from this spend to ensure Cigna can meet its reaffirmed 2026 guidance and ambitious adjusted EPS CAGR through 2030.
Cigna Sets Long-Term Goals, Unveils 2030 Modernization Strategy
The Cigna Group unveiled its "Lead to One" strategic growth framework, outlining long-term plans to transform healthcare by focusing on affordability and customer personalization. The company reaffirmed its 2026 financial outlook, targeting $280 billion in adjusted revenues and $30.45 adjusted EPS, and announced 2030 financial targets including a 10% to 14% adjusted EPS CAGR and $50 billion in cumulative operating cash flow. Cigna also launched a $3 billion modernization initiative to streamline operations, integrate AI, and optimize vendor management.
Cigna Group expects $3B in savings driven by AI, automation
The Cigna Group anticipates achieving $3 billion in savings, primarily through the implementation of artificial intelligence and automation technologies. This financial benefit is expected to be a key driver for future growth, as highlighted during the company's investor day, alongside its pharmacy initiatives.
Cigna (CI) Stock Looks Reasonable Against Its Earnings Power
Cigna (CI) stock currently trades at US$275.26, and its P/E ratio of 11.3x is significantly lower than the broader healthcare sector average of 24.2x. This suggests the stock may be undervalued based on its earnings power. While the company's performance has been mixed, analysts and internal narratives indicate potential for growth, particularly in specialty pharmacy and care services, suggesting the current price reflects a discount.
Cigna launches $3B cost-savings initiative focused on AI, automation
Cigna has announced a five-year initiative, "Accelerate to One," aiming to generate $3 billion in cost savings by 2030. This program will leverage AI and automation, improve workforce efficiency, and optimize supplier relationships. The savings will enhance productivity, lower operational costs, and free up capital for future investments.
Cigna Group (CI) Reaffirms FY26 Guidance Amid Investor Day Insig
Cigna Group (CI) reaffirmed its FY26 guidance during its Investor Day, leading to a significant stock decline as investors had hoped for stronger near-term growth indicators. The company presented a new $3 billion modernization initiative and maintained its long-term EPS growth algorithm, but did not elevate financial targets for FY26. The investment focus for Cigna now shifts to the execution of specialty pharmacy, medical-cost management, productivity, and capital deployment rather than revised financial projections.
Cigna (CI) Unveils $3 Billion AI Initiative, Reaffirms 2026 Guid
Cigna (CI) announced a $3 billion multi-year investment in AI and productivity tools to enhance performance and personalize healthcare services, reaffirming its 2026 financial guidance. The company targets $280 billion in adjusted revenue and at least $30.45 in adjusted EPS. Cigna also offers an attractive dividend yield of 2.35% with a low payout ratio, and its stock is significantly undervalued, trading 32.3% below its GF Value™.
Cigna to invest $3 billion in multi-year initiative to improve workflow
Cigna announced a $3 billion multi-year investment aimed at modernizing processes, streamlining workflows, and leveraging AI-enabled insights to drive growth. The health insurer expects annual adjusted earnings per share to grow 10% to 14% through 2030 and projects $50 billion in cash generation from operations over five years starting in 2026. Cigna also reiterated its 2026 forecast of $280 billion in revenue and at least $30.45 adjusted profit per share.
(FDS) FactSet Research Systems Expects Fiscal 2027 Revenue Range $2.60B - $2.63B, vs. FactSet Est of $2.61B
FactSet Research Systems Inc. (FDS) expects its fiscal year 2027 revenue to be in the range of $2.60 billion to $2.63 billion. This projection is in line with the FactSet estimate of $2.61 billion. The announcement was made following the company's Q4 results, where adjusted earnings and revenue rose.
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
Kailera Therapeutics has announced the completion of enrollment for its clinical trial of Ribupatide, a drug designed to treat obesity. Ribupatide, also known as KAI-9531, is a once-weekly injectable GLP-1/GIP receptor dual agonist currently in global Phase III trials, with the company also developing an oral tablet formulation. This development comes as Kailera continues to advance several GLP-1-based product candidates for obesity care.
Cigna unveils $3B modernization plan and targets 10-14% EPS growth through 2030 with new personalization strategy
Cigna announced its "Lead to One" vision, focusing on enhancing healthcare affordability and personalization through clinical expertise, data, and AI. The company is investing $3 billion in a multi-year modernization initiative, aiming for a 10-14% adjusted EPS compound annual growth rate through 2030. This strategy targets growth in complex care, operational discipline, and expanded capabilities across its Evernorth and Cigna Healthcare businesses.
The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
The Cigna Group hosted its 2026 Investor Day, unveiling its "Lead to One" vision aimed at driving durable growth by focusing on complex care leadership and differentiated capabilities. The company reaffirmed its 2026 financial guidance and provided long-term growth targets through 2030, including a 10-14% adjusted EPS CAGR and approximately $50 billion in cumulative operating cash flow. Cigna also announced a $3 billion multi-year modernization and productivity initiative to further fuel performance and enhance affordability and personalization in healthcare.
Cigna Group reaffirms 2026 outlook at investor day
The Cigna Group reaffirmed its full-year 2026 financial outlook during its Investor Day, projecting consolidated adjusted revenues of approximately $280 billion and adjusted earnings per share of at least $30.45. The company also set segment-level targets for Evernorth Health Services and Cigna Healthcare, alongside a long-term average annual adjusted EPS growth target of 10% to 14%. These figures were previously discussed in a July 2026 press release.
Cigna To Ramp Up Investments In Specialty Pharmacy And Complex Care
The Cigna Group is increasing its investments and company-wide focus on managing complex and specialized patient care within its health plans and healthcare services network. The company announced initiatives to improve access and experience for specialty care, leveraging data, clinical expertise, and AI through its "health intelligence engine" to personalize support and lower costs. These efforts include a new "Pharmacy Forward" program and plans to expand specialty care delivery sites and open a fifth "clean room" for compounding complex therapies.
The Cigna Group reaffirms 2026 guidance, unveils "Lead to One" and $3B modernization plan
The Cigna Group reaffirmed its 2026 financial outlook, projecting adjusted revenues of approximately $280 billion and consolidated adjusted EPS of at least $30.45. The company also introduced its "Lead to One" strategy to enhance personalization, affordability, and growth, alongside a $3 billion multi-year modernization and productivity plan. This initiative includes targets for Evernorth Health Services and Cigna Healthcare, and aims for a 10-14% adjusted EPS CAGR and roughly $50 billion cumulative operating cash flow through 2030.
Jefferies Adjusts Price Target on Brown & Brown to $68 From $70, Maintains Hold Rating
Jefferies has adjusted its price target for Brown & Brown (BRO) to $68, down from $70, while reiterating a "Hold" rating on the stock. This update comes as part of ongoing analyst evaluations for the multiline insurance and brokers company. The article also provides a company profile, recent news, and consensus analyst ratings for Brown & Brown.
CareSource, Molina to drop ACA Marketplace plans in Ohio in 2027
CareSource and Molina Healthcare of Ohio will exit the Affordable Care Act (ACA) Marketplace in Ohio in 2027, impacting approximately 54,000 current enrollees. CareSource cited rising healthcare costs and shifts in the ACA Marketplace as reasons for its decision, while Molina Healthcare Inc. reported declining profits and higher medical care ratios in its recent earnings. Ohioans affected by this change will need to select new plans during the open enrollment period for 2027, with nine other companies approved to sell individual plans on the exchange.
The Cigna Group stock after-hours at EUR 242.45: plus 1.66 percent versus prior close
The Cigna Group's stock increased by 1.66 percent to EUR 242.45 in after-hours trading on September 29, 2026. The company announced an agreement between its Cigna Global Health Benefits business and UnitedHealthcare Global, where UnitedHealthcare Global will endorse Cigna Global Health Benefits as its preferred international health insurer, withdrawing from the international private medical insurance business in several regions. Cigna Group also scheduled an Investor Day for September 30 to discuss corporate strategy and financial targets.
8% of hospital-insurer contract disputes go public: study
A new study in Health Affairs reveals that about 8% of hospital-insurer contract relationships escalated into public disputes between 2021 and 2025, but only 2% of these actually resulted in a contract dissolution. For-profit hospitals are twice as likely to engage in "brinkmanship," publicly threatening to leave an insurer's network to secure better rates, especially when they hold significant but not overwhelming local market power. This tactic is driven by hospitals seeking higher rates to cover rising costs and offset low federal reimbursement, with researchers noting a tension between affordability for consumers and the dramatic negotiation strategies employed by providers.
Transcript : Wheaton Precious Metals Corp. Presents at Mining Forum Americas 2026, Sep-29-2026 10:00 AM
Wheaton Precious Metals Corp. presented at the Mining Forum Americas 2026 on September 29, 2026, at 10:00 AM. The article provides a partial transcript of the presentation, featuring an introduction by analyst Matthew Murphy. The full content of the presentation is reserved for subscribers.
Cigna Stock in Focus as Investor Day Spotlights Specialty Drugs
Cigna Group's upcoming investor day, the first under new CEO Brian Evanko, will likely focus on the growth of its specialty pharmacy business. Wall Street is keen to hear updates on this sector, particularly regarding specialty drugs used for complex conditions like cancer, rather than just the company's traditional insurance operations.
No, the UnitedHealth AI-Denial Lawsuit Isn’t New. Here’s Where It Actually Stands.
This article clarifies that the UnitedHealth AI-denial lawsuit is not new, having been filed nearly three years ago. It details the case, Estate of Gene B. Lokken v. UnitedHealth Group, which alleges that UnitedHealth's nH Predict algorithm, with a 90% error rate, was used to deny care, particularly for Medicare Advantage patients. The lawsuit has survived challenges, leading to court-ordered disclosures and potentially significant implications for UnitedHealth and the broader health insurance industry regarding algorithmic care denials.
Westin Acquisition Corp Reports Earnings Results for the Full Year Ended June 30, 2026
Westin Acquisition Corp announced its earnings results for the full year ended June 30, 2026, reporting a net income of USD 0.890446 million. This financial update follows a recent merger deal with First Choice Healthcare Solutions and previous quarterly earnings reports. The company operates as a blank check company aiming for business combinations.
Have Cigna insurance? Your St. David’s care could cost more starting Thursday
Cigna health insurance plans may go out-of-network for St. David's HealthCare hospitals in Central Texas, Florida, and other HCA facilities starting Thursday, October 1, if a new agreement is not reached. This could lead to higher out-of-pocket costs for patients receiving care at St. David's hospitals. While emergency services will still be covered, other procedures and care may be subject to out-of-network rates, though some patients might qualify for continuity of care exceptions.
Cigna Group stock holds at USD 272.01 before investor day
Cigna Group's stock is holding at USD 272.01 ahead of its September 30 investor day, where the company's pharmacy benefit management strategy will be a key focus. This event follows stronger-than-expected Q2 2026 adjusted EPS of USD 7.78, surpassing the USD 7.60 consensus, despite revenue falling slightly short of estimates. Analysts have set price targets ranging from Evercore ISI's USD 290.00 to a broader average of USD 337.10, indicating the investor day is crucial for clarifying future growth amid a transition to a rebate-free PBM model.
